Search

The experimental study of the Ingavirin efficacy against the influenza virus A (H5N1) on intranasally-infected albino mice vs. Tamiflue and Arbidol showed that when used for the prophylaxis, urgent prophylaxis and therapy it was effective in the protectiom of the animals from death. The efficient dose for the prophylaxis of the influenza infection was 5 mg/kg (protective efficacy of 46.7%) and for the urgent prophylaxis and therapy it was 15 mg/kg (protective efficacy of 40.0 and 35.0% respectively).

High in vitro and in vivo efficacy of Ingavirin against the Mexican pandemic influenza virus A/H1N1/2009, strains A/California/04/2009 (H1N1) and A/California/07/2009 (H1N1) vs. the reference drug Arbidol was studied and verified when used therapeutically and prophylactically.

Ingavirin was shown to be efficient in inhibition of the influenza virus strains A/California/04/2009 and A/California/07/2009 (H1N1) in the MDCK cell culture. The coefficient of the cytopathic activity inhibition amounted to 50 and 60%, and the inhibition coefficients of the specific hemagglutinin formation were 50 and 50%, and 79,1 and 75% before and after the enrichment in chick embryos respectively.

The experimental investigation of Ingavirin activity against influenza B virus showed that in concentrations 100 and 200 mcg/ml it was efficient in inhibition of the virus reproduction: the cytopathic effect was lowered by 75%, the level of the pathogen accumulation in the MDCK cell culture was decreased by more than 2.0 lg and the formation of the virus specific hemagglutinin was inhibited by more than 90%.

The comparative analysis of the efficacy of Ingavirin and etiotropic chemotherapeutics, such as Arbidol and Remantadin, against the influenza virus A (H3N2) performed with the use of susceptible permanent cell cultures showed that in the used concentrations Ingavirin was efficient in inhibition of the virus cytopathic activity, formation of the specific hemagglutinin and reproduction of the virus (by the accumulation).

The experimental investigation of the Ingavirin antiviral effect showed that in concentrations of 200 and 100 mcg/ml it totally protected the cells from the cytopathic action of the virus, when added before the inoculation of the HeLa cell culture. After a tenfold decrease of the infective dose (up to 0.001 CPD50/cell), the inhibition of the virus cytopathic effect by Ingavirin amounted to 100% in all the tested concentrations (including the low ones) added either before or after the culture contamination. Ingavirin was efficient in inhibition of the adenovirus type 5 reproduction in the HeLa cell culture.

Investigation of the therapeutic efficacy of Ingavirin (Valenta Farmacevtica, Russia) against influenza virus A (H3N2) vs. Tamiflu, Remantadin and Arbidol showed that in daily doses of 15 and 20 mg/kg (equal by the efficacy to the human doses of 90 and 120 mg) Ingavirin was effective in protection of the albino mice infected by the virus in a dose of 10 to 15 LD50. The protective efficacy was 38.3-39.2% and the increase of the average lifespan amounted to 4.2-4.4 days. The Ingavirin efficacy was comparable with that of Remantadine, markedly exceeded that of Arbidol and was lower than that of Tamiflu. Investigation of the Ingavirin influence in doses of 15 and 20 mg/kg on the dynamics and level of the influenza virus A/Aichi/2/68 reproduction in the lungs of the infected albino mice weighing 10-12 g revealed that during the whole observation period in the doses tested Ingavirin was effective in inhibition of the influenza virus reproduction. During the whole period of the observation (5 days) Ingavirin was effective in inhibiting the formation of the virus specific hemagglutinin in the target organ.